Imagen de Portada

Surrogate Endpoints in Pivotal Clinical Trials for Drug Approval in Japan Compared to the United States

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuko Yamamoto, Harumi Kosaka, Hanami Nojiri, Hideki Maeda
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Clinical and Translational Science
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Retrospective Analysis of Master Protocols in Tumor‐Agnostic Drug Development: Evaluation of Application to Single‐Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs
por: Keiko Yamamoto, et al.
Publicado: (2025)

Surrogate Endpoints in Regulatory Decision‐Making
por: Linda J. B. Jeng, et al.
Publicado: (2025)

New Horizon in Clinical Development Strategy in Japan Based on New Guideline on Japanese Phase 1 Studies Prior to Multi‐Regional Clinical Trials
por: Kei Fukuhara, et al.
Publicado: (2025)

Informing Dose for Pediatric Rare Diseases—A Survey of Recent Orphan Drugs Approvals
por: Elimika Pfuma Fletcher, et al.
Publicado: (2026)

Impact of Dose‐Escalation Design on the Safety and Development of Anticancer Drugs in Clinical Trials
por: Atsushi Nonami, et al.
Publicado: (2025)

Modulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug–Placebo Differences
por: Martin Coenen, et al.
Publicado: (2025)

In Vitro Diagnostics for SARS ‐ CoV ‐2 Infection Authorized in the United States and Approved in Japan
por: Mayumi Idei, et al.
Publicado: (2025)

Clinical Evaluation of Drug–Drug Interactions With Aficamten
por: Neha Maharao, et al.
Publicado: (2026)

Navigating Drug–Drug Interactions in Clinical Drug Development: A Tutorial
por: Jesmin Lohy Das, et al.
Publicado: (2025)

High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment
por: Eric J. Lenze, et al.
Publicado: (2025)

Age‐related off‐label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and Japan
por: Bojung Park, et al.
Publicado: (2024)

Representation of Older Adult Patients in Clinical Trials
por: Sebastian Haertter, et al.
Publicado: (2025)

Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies
por: Tomohiro Kamimura, et al.
Publicado: (2024)

Clinical Significance of Drug–Drug Interaction Studies During Therapeutic Peptide Drug Development: Follow‐Up Investigation of Therapeutic Peptides Approved Between 2021 and 2024
por: Carolina Säll, et al.
Publicado: (2025)

Development and Validation of an Approach to Assessing Clinical Relevance of Potential Drug–Drug Interactions Inducing Rare but Serious Adverse Events
por: Menghuan Song, et al.
Publicado: (2025)

Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority
por: Mark J. Ratain, et al.
Publicado: (2025)

Association of Protocol Design‐Related Factors With Enrollment Duration in Clinical Trials
por: Hiroaki Tsuchiya, et al.
Publicado: (2026)

Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling
por: Flavia De Toni, et al.
Publicado: (2026)

Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective
por: Jie Chen, et al.
Publicado: (2025)

Exploration of Using an Open‐Source Large Language Model for Analyzing Trial Information: A Case Study of Clinical Trials With Decentralized Elements
por: Ki Young Huh, et al.
Publicado: (2025)

Understanding Motivation to Participate in Clinical Trials: Insights to Diversify Clinical Research Using Health Information National Trends Survey
por: Rifath Ara Alam Barsha, et al.
Publicado: (2026)

Unlocking the Mysteries of Rare Disease Drug Development: A Beginner's Guide for Clinical Pharmacologists
por: Mariam A. Ahmed, et al.
Publicado: (2025)

Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates
por: Paulien Ravenstijn, et al.
Publicado: (2026)

Positioning Community Pharmacies in Nigeria as a Clinical Trial Partner: A Forward Perspective
por: Adeboye O. Bamgboye, et al.
Publicado: (2026)

A Randomized Hybrid‐Effectiveness Trial Comparing Pharmacogenomics (PGx) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care (PGx‐ACT) Trial
por: D. Max Smith, et al.
Publicado: (2025)

Clinical Pharmaceutical Care in Nursing Home Residents as a Cornerstone for Drug‐Related Problems Identification
por: Milada Halačová, et al.
Publicado: (2025)

Decentralized Clinical Trials in the Era of Real‐World Evidence: A Critical Assessment of Recent Experiences
por: Hongwei Wang, et al.
Publicado: (2025)

Tutorial Drug–Drug Interactions
por: Edward M. Sellers
Publicado: (2025)

Cross‐Reactive NSAID Hypersensitivity: Clinical Findings From Aspirin Provocation and Alternative Drug Challenge Testing
por: Young‐Il Koh, et al.
Publicado: (2025)

From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry
por: Wonseok Yang, et al.
Publicado: (2025)

Insights From a User Experience‐Focused Virtual Study on the Feasibility and Challenges of Decentralized Clinical Trials
por: Yue Ma, et al.
Publicado: (2025)

Critical Roles for Modeling and Simulation and Real‐World Evidence to Inform Challenges in Clinical Trial Diversity Planning
por: Ananth Kadambi, et al.
Publicado: (2025)

Predictors of Clinical Trial Participation Among Older U.S. Adults With Multimorbidity: A Cross‐Sectional Survey
por: Janice B. Schwartz, et al.
Publicado: (2026)

Modulation of Inflammatory Indices by Omega‐3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach
por: Hanieh Shafaei Kachaei, et al.
Publicado: (2026)

Surfing the T Wave: A Primer on ECG T Wave Morphologies Encountered in Clinical Trials and Impact on the QT Interval and Patient Safety
por: Robert M. Lester, et al.
Publicado: (2025)

Mass Balance and Metabolism of 14 C ‐Atogepant in Healthy Male Participants: Findings of a Phase 1 Clinical Trial
por: Ramesh R. Boinpally, et al.
Publicado: (2025)

Inter‐Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials
por: Nicki M. Kyriacou, et al.
Publicado: (2025)

Effects of Siltuximab Versus Corticosteroids in Preventing COVID −19 Pneumonia Disease Progression: Multicentre, Open‐Label, Randomized Clinical Trial
por: Lorna Leal, et al.
Publicado: (2026)

Comparison of Different Machine Learning Methodologies for Predicting the Non‐Specific Treatment Response in Placebo Controlled Major Depressive Disorder Clinical Trials
por: Roberto Gomeni, et al.
Publicado: (2025)

A Pilot Study to Explore Length and Readability Characteristics of Subject Information Sheets/Informed Consent Forms of Clinical Trial Applications in the EU
por: Sophie Brunner Ziegler, et al.
Publicado: (2026)